Opinion|Videos|September 30, 2024
Emerging Research of RNAi-Based Therapies for FCS
Panelists discuss how early diagnosis and intervention in familial chylomicronemia syndrome (FCS) are crucial for preventing cardiovascular and metabolic complications, emphasizing the key role clinicians play in initiating timely and effective treatment strategies.
Advertisement
Video content above is prompted by the following:
What are the benefits of early diagnosis and intervention in familial chylomicronemia syndrome for preventing cardiovascular and metabolic complications, and what role do clinicians play in this process?
Advertisement
Related to this article
This Q&A interview segment with Harrison Nguyen, MD, MBA, MPH, highlights key points made during his 2026 Fall Clinical Dermatology meeting sessions.
Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.
Phase 2 BESTOW patient-reported outcomes show greater quality-of-life gains and fewer medication-related symptoms with tegoprubart vs tacrolimus at 1 year.
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Advertisement
Advertisement
Trending on HCPLive
1
eGFR Underestimates CKD in Patients with Cancer, Study Finds
2
Tegoprubart Improves Quality of Life vs Tacrolimus After Kidney Transplant
3
The HCPFive: Top News for Healthcare Providers from the Week of 10/18
4
42% on Povetacicept Reach KDIGO-Aligned UPCR Target in RAINIER
5